Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director | September 24, 2026 | October 05, 2026 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | August 10, 2026 | August 12, 2026 |
| Spectrum Brands Holdings, Inc.SPB · Entity 4515 | Director | December 12, 2025 | December 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date September 24, 2026 · Filed October 05, 2026
This filing explicitly reported no securities owned.
Amneal Pharmaceuticals, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy Limited Liability Company | 283,632 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 283,632 · Balance 283,632 F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition. |
| Class A Common StockSEC Table I · non-derivative | Direct | 1,643,963 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,643,963 |
Filing footnotes · ownership attribution and instrument terms
F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition.
Spectrum Brands Holdings, Inc.
Report date December 12, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,141 |
Reported balance
After 2025-12-12 transaction · row 1
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 4,602 · Balance 22,141 F1: The Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2026 if the Reporting Person is a director of the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was awarded restricted stock units which are settled in shares of common stock of the Issuer and which are scheduled to vest on October 1, 2026 if the Reporting Person is a director of the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000073 · wf-form4_155735216396679.xml · derivative · entry 3 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. The restricted stock units do not expire. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. The restricted stock units do not expire. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000073 · wf-form4_155735216396679.xml · derivative · entry 2 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 21:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherCommon Units · Derivative | 30,384,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019667 · doc4.xml · derivative · entry 2 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 30,384,769 Underlying: Common Units · 30,384,769 shares Expires not disclosed F3 · derivative.exercise_price: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F1 · kind: Represents a pro rata in-kind distribution of Class B Common Stock and Common Units from APHC Holdings, LLC to its members for no consideration. F3 · derivative.exercise_date: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F3 · derivative.expiration_date: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F2 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 21:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass B Common Stock | 30,384,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019667 · doc4.xml · nonDerivative · entry 1 Patel Gautam · CIK 0001738054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 30,384,769 F1 · kind: Represents a pro rata in-kind distribution of Class B Common Stock and Common Units from APHC Holdings, LLC to its members for no consideration. F2 · ownership.nature: By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:36 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012160 · doc4.xml · derivative · entry 2 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:36 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-012160 · doc4.xml · derivative · entry 1 Patel Gautam · CIK 0001738054 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.